Evolus Gets EU Approval for Treatment of Wrinkles

By Connor Hart. Evolus has received European Union Medical Device Regulation certification for its injectable hyaluronic acid gels, which are dermal fillers for the treatment of wrinkles and folds.

22%
OFF

Evolus Q3 Revenue Surges 22% To $61.1M, Wins EU Approval For …

1 week from now

Nov 6, 2024 · Evolus (NASDAQ: EOLS) reported Q3 2024 total net revenue of $61.1 million, up 22% from Q3 2023, with year-to-date growth of 33%.The company received EU approval for …

stocktitan.net

FAQs about Evolus Gets EU Approval for Treatment of Wrinkles Coupon?

Does Evolus have hyaluronic acid?

By Connor Hart Evolus has received European Union Medical Device Regulation certification for its injectable hyaluronic acid gels, which are dermal fillers for the treatment of wrinkles and folds. ...

What is Evolus ®?

Evolus is a performance beauty company building an aesthetic portfolio of consumer brands in the cash-pay aesthetic market. Our flagship product is Jeuveau ®, a proprietary neurotoxin formulation used in adults to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). ...

What does Evolus certification mean for the dermal filler industry?

This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the dermal filler segment and doubling its addressable market outside the U.S. to $1.8 billion 1. ...

Does Evolus have a limited experience program?

Evolus plans to offer the treatment through a limited experience program with select physician partners. This limited release will enable the company to refine its broader European launch strategy, which is expected to occur in the second half of next year. ...

How will Evolus introduce estyme ®?

Evolus will introduce Estyme ® through a limited experience program with select physician partners. The limited experience program will allow Evolus to collaborate with leading aesthetic practitioners across Europe, gathering valuable insights to refine its broader launch strategy. A broader European launch is planned for the second half of 2025. ...

Will estyme evolysse reach $1.8 billion?

Certification of the treatment Estyme--branded as Evolysse in the U.S. market--is a key regulatory milestone, enabling it to double its addressable market outside of the U.S. to $1.8 billion, the beauty company said Thursday. Evolus plans to offer the treatment through a limited experience program with select physician partners. ...